Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunodynamics-Guided PD-1 Inhibitor Timing in Advanced NSCLC
NCT07190027Phase 2Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Wenzhou Medical University
- Start
- Nov 2025
- Primary completion
- Nov 2025
01
Overview
Phase 2, randomised, open-label trial in non-small cell lung cancer (NSCLC) (3 arms), sponsored by The First Affiliated Hospital of Wenzhou Medical University. Primary endpoint: Objective Response Rate up to 36 months. Planned start Nov 2025; status: not yet recruiting.
02
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07190027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07190027.